Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. (P2.8-047) - Concepedia

Concepedia

Publication | Closed Access

Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. (P2.8-047)

11

Citations

0

References

2019

Year

Andrew M. Goldfine, Robert Faulkner, S. Vasu, Omid Omidvar, John M. Hill, Singaravelu Jagadeesan, Anil Prakash Sharma, Siu‐Long Yao

Abstract

To determine the safety and efficacy of K0706, a novel c-Abl tyrosine kinase inhibitor (TKI), to slow the progression of Parkinson’s disease.